Anifrolumab Early Access Program (AMANA)
An Early Access Program for Anifrolumab Treatment in Adult Patients With Active Systemic Lupus Erythematosus - AMANA
Sponsor: AstraZeneca
A observational or N/A phase clinical study on Systemic Lupus Erythematosus, this trial is ongoing. The trial is conducted by AstraZeneca and has accumulated 4 data snapshots since 2026. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
4 versions recorded-
Sep 2024 — Present [monthly]
No Longer Available
-
Jul 2024 — Sep 2024 [monthly]
No Longer Available
-
Jun 2021 — Jul 2024 [monthly]
No Longer Available
Status: Available → No Longer Available
-
Mar 2021 — Jun 2021 [monthly]
Available
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- AstraZeneca
- Clinigen, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.